Patents Assigned to SpyGlass Pharma, Inc.
  • Patent number: 11903874
    Abstract: An ophthalmic implant including an intraocular lens (IOL) and at least one drug delivery device. The IOL including an anterior side, a posterior side, a lens, and at least one haptic extending outwardly from the lens and including a first haptic extending from the lens at a first optic-haptic junction. The at least one drug delivery device including a first drug delivery device including a pad and a fixation portion extending from the pad. The pad including at least one therapeutic agent contained therein, an anterior surface, a posterior surface, and a sidewall extending around the pad and between the anterior surface and the posterior surface. The drug delivery device configured for attachment to the IOL via the fixation portion. In an assembled state of the implant, the first drug delivery device is attached to the IOL and the pad overlays the first optic-haptic junction.
    Type: Grant
    Filed: March 7, 2023
    Date of Patent: February 20, 2024
    Assignees: SpyGlass Pharma, Inc., The Regents of the University of Colorado, a body corporate
    Inventors: James R. Dennewill, Malik Y. Kahook, Glenn R. Sussman, Craig Alan Cable, II
  • Patent number: 11883277
    Abstract: An ophthalmic implant including an IOL with haptics, and drug delivery devices secured to the haptics. The posterior-most extent of the drug delivery device is located anterior to the posterior edge or PCE barrier edge, of the IOL. In other configurations, the drug delivery devices are provided with PCO barrier edges.
    Type: Grant
    Filed: September 16, 2022
    Date of Patent: January 30, 2024
    Assignees: SpyGlass Pharma, Inc., The Regents of the University of Colorado, a body corporate
    Inventors: Craig Alan Cable, II, Glenn R. Sussman, James R. Dennewill, Malik Y. Kahook
  • Patent number: 11813159
    Abstract: An intraocular drug delivery platform for use with an intraocular lens assembly. The platform includes a ring and haptics to maintain the ring in position in the capsular bag, compartments on the anterior surface of the ring for accommodating a drug eluting matrix or other drug mass, and a skirt extending posteriorly from the posterior surface of the ring to constrain movement, including lateral or inferior/superior movement, of the intraocular lens relative to the ring.
    Type: Grant
    Filed: February 24, 2021
    Date of Patent: November 14, 2023
    Assignees: SpyGlass Pharma, Inc., The Regents of the University of Colorado, a body corporate
    Inventors: Glenn Robert Sussman, Craig Alan Cable, II, Malik Y. Kahook
  • Patent number: 11806227
    Abstract: This disclosure provides ophthalmic implants such as sulcus implants which can comprise one or more drug delivery devices. Further provided herein are methods of using the drug delivery ophthalmic devices described herein for implantation into a subject's eye, e.g., into an eye's ciliary sulcus or capsular bag.
    Type: Grant
    Filed: September 28, 2022
    Date of Patent: November 7, 2023
    Assignees: SpyGlass Pharma, Inc., The Regents of the University of Colorado, a body coporate
    Inventors: Craig Alan Cable, II, Malik Y. Kahook, Glenn R. Sussman, James R. Dennewill
  • Patent number: 11779457
    Abstract: Embodiments disclosed herein relate to systems and methods for securing a drug delivery component to an intraocular lens (IOL) assembly. The systems generally include a support base and a plunger. The support base includes a first portion configured to accommodate a drug delivery component; and a second portion configured to act as a plunger guide. The plunger can be inserted into the plunger guide such that the plunger is positioned to interface with a drug delivery component and an IOL assembly during use. The plunger includes an elongated body and a tip, wherein the tip can include a ramp configured to interface with a fixation loop of a drug delivery component during use and a compartment configured to interface with a haptic of an IOL assembly during use.
    Type: Grant
    Filed: September 16, 2022
    Date of Patent: October 10, 2023
    Assignees: SpyGlass Pharma, Inc., The Regents of the University of Colorado, a body Corporate
    Inventors: Craig Alan Cable, II, Malik Y. Kahook, Sean Maass, Rudolph Zacher
  • Patent number: 11771592
    Abstract: Embodiments disclosed herein generally relate to a stabilized intraocular drug delivery system for implantation into an eye of a subject. The system can include an intraocular lens (IOL) assembly and a drug delivery component. The IOL assembly can include a lens and a haptic. The haptic can include an outer end, an inner end opposite the outer end, a retention tab at the inner end, and a connection tab positioned between the outer end and the inner end and adjoining the lens. The drug delivery component can include at least one therapeutic agent and a fixation portion having an opening to receive the haptic and secure the drug delivery component to the IOL assembly. The fixation portion of the drug delivery component can be secured to the connection tab of the haptic such that the retention tab inhibits movement of the drug delivery component relative to the IOL assembly.
    Type: Grant
    Filed: September 16, 2022
    Date of Patent: October 3, 2023
    Assignees: SpyGlass Pharma, Inc., The Regents of the University of Colorado, a body Corporate
    Inventors: Craig Alan Cable, II, Malik Y. Kahook, Glenn R. Sussman, Sean Maass
  • Patent number: 11654014
    Abstract: An ophthalmic implant including an IOL with haptics, and drug delivery devices secured to the haptics. The posterior-most extent of the drug delivery device is located anterior to the posterior edge or PCE barrier edge, of the IOL. In other configurations, the drug delivery devices are provided with PCO barrier edges.
    Type: Grant
    Filed: December 1, 2021
    Date of Patent: May 23, 2023
    Assignees: SpyGlass Pharma, Inc., The Regents of the University of Colorado
    Inventors: Craig Alan Cable, II, Glenn R. Sussman, James R. Dennewill, Malik Y. Kahook
  • Patent number: 11617681
    Abstract: An ophthalmic implant configured for peri-operative, intra-operative, or post-operative assembly and disassembly. Drug delivery devices may be implanted with an intraocular lens, and later removed and replaced with new drug delivery devices.
    Type: Grant
    Filed: June 14, 2022
    Date of Patent: April 4, 2023
    Assignees: SpyGlass Pharma, Inc., The Regents of the University of Colorado, a body Corporate
    Inventors: James R. Dennewill, Malik Y. Kahook, Glenn R. Sussman, Craig Alan Cable, II
  • Patent number: 11399977
    Abstract: An ophthalmic implant configured for peri-operative, intra-operative, or post-operative assembly and disassembly. Drug delivery devices may be implanted with an intraocular lens, and later removed and replaced with new drug delivery devices.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: August 2, 2022
    Assignees: SPYGLASS PHARMA, INC., THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: James R. Dennewill, Malik Y. Kahook, Glenn R. Sussman, Craig Alan Cable, II
  • Patent number: 11298262
    Abstract: An ophthalmic implant for drug delivery. The implant includes a primary intracapsular device coupled to a secondary device, wherein, when implanted in a patient's eye, the primary intracapsular device is held in place by the patient's capsular bag and the secondary device is held in place by the primary intracapsular device. The implant may be inserted in the eye by injecting the primary intracapsular device into the eye either before or after attaching the secondary device to the primary intracapsular device, and subsequently positioning the joined secondary device and primary intracapsular device with the primary intracapsular device held in place by the patient's capsular bag and the secondary device held in place by the primary intracapsular device. The secondary device may be designed to hold a tertiary device that can be implanted and attached at the time of surgery or anytime postoperatively.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: April 12, 2022
    Assignees: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE, SPYGLASS PHARMA, INC.
    Inventors: Malik Y. Kahook, Glenn Sussman, Craig Alan Cable, II
  • Publication number: 20220104936
    Abstract: An ophthalmic implant including an IOL with haptics, and drug delivery devices secured to the haptics. The posterior-most extent of the drug delivery device is located anterior to the posterior edge or PCE barrier edge, of the IOL. In other configurations, the drug delivery devices are provided with PCO barrier edges.
    Type: Application
    Filed: October 5, 2020
    Publication date: April 7, 2022
    Applicants: SpyGlass Pharma, Inc., The Regents of the University of Colorado, a body corporate
    Inventors: Craig Alan Cable, II, Glenn R. Sussman, James R. Dennewill, Malik Y. Kahook
  • Publication number: 20210378861
    Abstract: An ophthalmic implant configured for peri-operative, intra-operative, or post-operative assembly and disassembly. Drug delivery devices may be implanted with an intraocular lens, and later removed and replaced with new drug delivery devices.
    Type: Application
    Filed: June 4, 2020
    Publication date: December 9, 2021
    Applicants: SpyGlass Pharma, Inc., The Regents of the University of Colorado, a body corporate
    Inventors: James R. Dennewill, Malik Y. Kahook, Glenn R. Sussman, Craig Alan Cable, II
  • Publication number: 20210267751
    Abstract: An intraocular drug delivery platform for use with an intraocular lens assembly. The platform includes a ring and haptics to maintain the ring in position in the capsular bag, compartments on the anterior surface of the ring for accommodating a drug eluting matrix or other drug mass, and a skirt extending posteriorly from the posterior surface of the ring to constrain movement, including lateral or inferior/superior movement, of the intraocular lens relative to the ring.
    Type: Application
    Filed: February 24, 2021
    Publication date: September 2, 2021
    Applicants: SpyGlass Pharma, Inc., The Regents of the University of Colorado, a body corporate
    Inventors: Glenn Robert Sussman, Craig Alan Cable, II, Malik Y. Kahook